Hairy Cell Leukemia Patient Data Registry

This study is creating a registry, which is a collection of de-identified (anonymous) patient information, for people with hairy cell leukemia (HCL) or its variant. The goal is to help researchers better understand HCL, find the most effective treatments, discover new complications, and design future studies for new therapies. This registry will collect information about your symptoms, how your disease progresses, complications from the disease and its treatment, and other important details over a long period of time. This is an observational study, meaning researchers will collect information without giving you any specific interventions or treatments as part of the study.

Study design
This is an observational study that aims to collect data from up to 5000 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your information will be collected and followed for up to 25 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02560883

Hairy Cell Leukemia Patient Data Registry

Recruiting
Not specifiedAges 18+Observational
Ohio State University Comprehensive Cancer Center
~5,000 participants
Updated 2026-07-02 on ClinicalTrials.gov

At a glance

Recruiting sites
8 of 8 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Surveillance
Measured over up to 25 years
Leukemia, Other
8 sites across 7 states
Florida2
Minnesota1
New York1
Ohio1
Victoria1
Britsh Columbia1
Manitoba1
  • Michael Grever, MD · PRINCIPAL_INVESTIGATOR · The Ohio State University Comprehensive Cancer Center
Hairy Cell Leukemia Research Data Registry
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

  • Surveillanceup to 25 years

    Establish a database of Hairy Cell Leukemia patients diagnosed or living in US to track Hairy Cell Leukemia disease course, patient reported outcomes, morbidity, and patient survival.